COVID-19

Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines

04/20/2021

Excerpt from the Press Release: LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the peer-reviewed publication of preclinical results of its COVID-19 vaccine candidate, MRT5500, in the journal npj Vaccines. Preclinical evaluation of MRT5500 demonstrated a favorable immune response profile against SARS-CoV-2 and…

Read More

Scientists Reverse Engineer mRNA Sequence of Moderna Vaccine

04/16/2021

Excerpt from the Article: Leftover drops in vials of Moderna’s COVID-19 vaccine allowed a group of researchers from Stanford University to determine the sequence of the mRNA for SARS-CoV-2’s spike protein that is used in the immunization, Motherboard reported March 29. The sequence has been posted on the open-access website GitHub. “Sharing of sequence information…

Read More

Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine

04/15/2021

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today highlighted the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in The New England Journal of Medicine. “We are pleased that this new…

Read More

Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

04/14/2021

Excerpt from the Press Release: INDIANAPOLIS, April 8, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today results of COV-BARRIER, a Phase 3 study evaluating baricitinib 4 mg once daily plus standard of care (SoC) versus placebo plus SoC. The trial did not meet statistical significance on the primary endpoint, which…

Read More

Penn Medicine Researcher Awarded $1 Million to Expand COVID-19 Treatment Discovery Platform

04/07/2021

Excerpt from the Press Release: PHILADELPHIA —  David C. Fajgenbaum, MD, MBA, MSc, an assistant professor of Translational Medicine & Human Genetics and director of the Center for Cytokine Storm Treatment & Laboratory at the Perelman School of Medicine at the University of Pennsylvania, was awarded $1 million by the Parker Institute for Cancer Immunotherapy…

Read More

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

04/06/2021

Excerpt from the Press Release: WARMINSTER, Pa. and WALTHAM, Mass. and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered into a discovery research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2…

Read More

CureVac’s COVID-19 mRNA vaccine protects mice against aggressive coronavirus variant

04/02/2021

Excerpt from the Press Release: The preclinical study found CureVac’s candidate, dubbed CVnCoV, protected mice against COVID-19 in a virus challenge study with the B.1.351 variant of the SARS-CoV-2 virus. The variant, first identified in South Africa, bears certain mutations that make it more contagious than the original virus. It marks the first mouse challenge…

Read More

Meissa’s Nasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses

03/30/2021

Excerpt from the Article: Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March. Unlike other live attenuated virus vaccines, it employs codon deoptimization to evoke a stronger-than-usual immune response. If approved, it holds the potential of…

Read More

Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients

03/29/2021

Excerpt from the Press Release: SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC™) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). This ongoing study (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for…

Read More

AZD1222 US Phase III Trial Met Primary Efficacy Endpoint in Preventing COVID-19 at Interim Analysis

03/26/2021

Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization. This interim safety and efficacy analysis was based on 32,449 participants accruing 141 symptomatic cases of COVID-19. The trial had…

Read More